The strength in the stock has been exceptional. It has moved strongly over the last one month, when many stocks have corrected with the market. It is now about 70% up from its 52 week low of $4.97. The good results in the last quarter and the expectations of a turnaround are helping the stock to gain momentum. The price already has factored a lot of the positives related to the turnaround, and may need a stronger positive surprise in the next quarter to keep going. However, it is still strong, and thus the trend can be followed. As a matter of caution, one can follow it with a trailing stop loss. The main trigger will be the earnings in a month from now. That will decide the short term future of the stock. If it is able to beat the guidance or post a quarter of profit or improve its performance, it may be able to move to the next zone pretty quickly. The fact that it does not have any debt makes things better. Negative surprises will have a harsher effect so one needs to decide how to play it. In a run up to the event, the stock may remain in a tight range if the overall market does not weaken significantly. For growth it is more dependent on the performance of third party products as they contribute 75% to the revenues. So some new, high growth potential, better margin products from these parties would surely help. Chromadex (CDXC) recently launched Nicotinamide Riboside (NR) which is a vitamin molecule with a lot of potential for its use in numerous indications. Other small and big companies are also launching numerous innovative products in the market which are likely to help in improving growth and margins. Vitacost can select the product from a company which is more in line with its own segment focus / strategy. Next earnings will be extra crucial.
